DURHAM, Caroline du Nord, 24 juin 2025 (GLOBE NEWSWIRE) — Read more »
Fortrea und Emery Pharma kündigen strategische Zusammenarbeit zur Durchführung FDA-konformer Arzneimittelwechselwirkungsstudien mit Rifampin an
Durham, North Carolina, June 24, 2025 (GLOBE NEWSWIRE) — Read more »
Fortrea & Emery Pharma Announce Strategic Collaboration to Deliver FDA Compliant Drug-Drug-Interaction Studies Using Rifampin
DURHAM, N.C., June 24, 2025 (GLOBE NEWSWIRE) — Read more »
Noted Vaccine Researcher and Leader Kate O’Brien Awarded Sabin’s Gold Medal; Physician Livancliff Mbianke of Cameroon Receives Rising Star Award
WASHINGTON, May 13, 2025 (GLOBE NEWSWIRE) — The Sabin Vaccine Institute today awarded the Albert B. Sabin Gold Medal to pediatrician Katherine O’Brien, MD, MPH, for her research on the pneumococcal vaccine and [...] Read more »
Entera Bio Announces First Quarter 2025 Financial Results and Business Updates
JERUSALEM, May 09, 2025 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for [...] Read more »
Sabin Begins Marburg Vaccine Trial in U.S.
WASHINGTON, April 16, 2025 (GLOBE NEWSWIRE) — The Sabin Vaccine Institute has launched a multi–site Phase 2 clinical trial in the U.S. for its Marburg vaccine candidate, administering doses to the [...] Read more »
Minovia Therapeutics Announces FDA Clearance of Second IND Application, for a Phase II Clinical Trial of Lead Product MNV-201 in Pearson Syndrome
MNV–201 is Minovia’s second generation mitochondrial cell therapy product composed of autologous hematopoietic stem cells enriched with allogeneic mitochondria
Read more »
Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates
JERUSALEM, March 28, 2025 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, today reported financial results and key business [...] Read more »
Curia annonce l’extension de son réseau mondial de sites de remplissage et de finition stériles
ALBANY, État de New York, 17 mars 2025 (GLOBE NEWSWIRE) — Curia Global, Inc. (Curia), une organisation leader du domaine de la recherche, du développement et de la fabrication sous contrat, dévoile ce jour les [...] Read more »
Curia Announces Expansions to Global Network of Sterile Fill-Finish Sites
ALBANY, N.Y., March 17, 2025 (GLOBE NEWSWIRE) — Curia Global, Inc. (Curia), a leading contract research, development and manufacturing organization, today announced expansion plans to its Glasgow, UK facility and [...] Read more »
Curia kündigt Erweiterung des globalen Netzwerks steriler Abfüllanlagen an
ALBANY, N.Y., March 17, 2025 (GLOBE NEWSWIRE) — Curia Global, Inc. (Curia), ein führendes Unternehmen für Auftragsforschungs–, Entwicklungs– und Produktionsunternehmen, gab heute Expansionspläne für [...] Read more »
Curia Anuncia Expansão da Rede Global de Locais de Processamento Final Estéril
ALBANY, N.Y., March 17, 2025 (GLOBE NEWSWIRE) — A Curia Global, Inc. (Curia), uma organização líder em contratos de pesquisa, desenvolvimento e fabricação, anunciou hoje planos de [...] Read more »
OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders
MIAMI and JERUSALEM, March 17, 2025 (GLOBE NEWSWIRE) — OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, entered into [...] Read more »
VIVUS تطلق عقار QSYMIA® في الإمارات العربية المتحدة
– علاج جديد في Read more »
VIVUS Launches QSYMIA® in the United Arab Emirates
– A new path in weight management is now available
– UAE is the first country in the Middle East to have QSYMIA® available
Read more »